Literature DB >> 29442279

Robust estimation in accelerated failure time models.

Sanjoy K Sinha1.   

Abstract

The accelerated failure time model is widely used for analyzing censored survival times often observed in clinical studies. It is well-known that the ordinary maximum likelihood estimators of the parameters in the accelerated failure time model are generally sensitive to potential outliers or small deviations from the underlying distributional assumptions. In this paper, we propose and explore a robust method for fitting the accelerated failure time model to survival data by bounding the influence of outliers in both the outcome variable and associated covariates. We also develop a sandwich-type variance-covariance function for approximating the variances of the proposed robust estimators. The finite-sample properties of the estimators are investigated based on empirical results from an extensive simulation study. An application is provided using actual data from a clinical study of primary breast cancer patients.

Entities:  

Keywords:  Failure time model; Hazard function; Outliers; Robust estimation; Survival data

Mesh:

Year:  2018        PMID: 29442279     DOI: 10.1007/s10985-018-9421-z

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  5 in total

1.  New residuals for Cox regression and their application to outlier screening.

Authors:  A Nardi; M Schemper
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Authors:  L J Wei
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

3.  Robust estimation for the Cox regression model based on trimming.

Authors:  Alessio Farcomeni; Sara Viviani
Journal:  Biom J       Date:  2011-11       Impact factor: 2.207

4.  A robust method for proportional hazards regression.

Authors:  C E Minder; T Bednarski
Journal:  Stat Med       Date:  1996-05-30       Impact factor: 2.373

5.  A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Authors:  Maïa Chanrion; Vincent Negre; Hélène Fontaine; Nicolas Salvetat; Frédéric Bibeau; Gaëtan Mac Grogan; Louis Mauriac; Dionyssios Katsaros; Franck Molina; Charles Theillet; Jean-Marie Darbon
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.